Patients must not have experienced a grade  or worse immune-related adverse event (irAE) (except asymptomatic nonbullous/nonexfoliative rash) or any unresolved irAE grade , nor have experienced a toxicity that led to permanent discontinuation of prior anti-PD-/PD-L immunotherapy
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Patient has had a prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior >= grade  immune-related adverse event (irAE) while receiving immunotherapy, or any unresolved irAE > grade 
Any history of a prior >= grade  immune-related adverse event (irAE) while receiving any previous immunotherapy agent
Patient has had a prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Have had any prior Grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, have any unresolved irAE Grade >, or any irAE that led to the permanent discontinuation of prior immunotherapy.
Any prior grade ?  immune-related adverse event (irAE) while receiving a prior immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Participants with any prior >= grade  immune-related adverse event (irAE) which began while receiving immunotherapy
Participants with any unresolved immune-related adverse event (irAE) at time of study entry\r\n* Note: Subjects with =< grade  thyroiditis and/or hypophysitis are an exception to this criterion and may qualify for the study
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior immune-related adverse event (irAE) >= grade  while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Patient has had a prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade .
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy; any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade ?  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved immune related adverse events (irAE) > grade 
Must not have had a grade >=  immune related adverse event (irAE) on nivolumab monotherapy (excluding endocrine toxicity managed with replacement therapy)
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nAny prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade  as per National Cancer Institute (NCI)-CTCAE v.; patients with greater than + proteinuria at entry are ineligible
PHASE II STUDY COHORT  OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nAny prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade  as per NCI-CTCAE v.; patients with greater than + proteinuria at entry are ineligible
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade  as per NCI-CTCAEv.
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT  ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nAny prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade  as per NCI-CTCAEv.; patients with greater than + proteinuria at entry are ineligible
Any prior grade >=  immune-related adverse event (irAE) while receiving immunotherapy (including anti-cytotoxic T-lymphocyte antigen  [CTLA-] or anti-cluster of differentiation [CD] monoclonal antibody [MAb]) or any unresolved irAE of any grade (controlled irAE endocrinopathies are allowed)
Must not have experienced an immune-related adverse event (irAE) where the irAE was the reason for permanent discontinuation of prior immunotherapy in the most recent prior treatment regimen
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Has any prior Grade ? immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA- treatment, or any unresolved irAE >Grade .
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade  except for endocrine adverse events (AEs) managed with replacement therapy; any other AEs unresolved toxicities grade  or more from previous anti-cancer therapy, except alopecia, peripheral neuropathy or non-clinically significant lab abnormalities
DOSE ESCALATION COHORT: Any prior ? grade  immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA- and anti-PD-/PD-L treatment, or any unresolved irAE > grade \r\n* Note: Previous immune-related ocular toxicity of any grade is excluded
DOSE EXPANSION COHORT: Any prior ? grade  immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA- and anti-PD-/PD-L treatment, or any unresolved irAE > grade ; Note: previous immune-related ocular toxicity of any grade is excluded
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Patients must not have any prior grade >=  immune-related adverse event (irAE) or any unresolved irAE > grade 
Patients must not have any prior grade >=  immune-related adverse event (irAE) or any unresolved irAE > grade  (MEDI RE-TREATMENT)
Any prior Grade ?  immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior Grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 
Any prior Grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 
Any prior Grade ?  immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE.
Any prior Grade ?  irAE while receiving immunotherapy
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any prior grade >=  immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 
Any clinically significant Grade ? immune-related adverse event (irAE)
Any grade neurologic or ocular irAE
For Arms L (pembrolizumab) and M (nivolumab), history of a prior grade  or  immune-related adverse event (irAE) or any grade ocular irAE from prior immunotherapy
